Integrative multi-omics and drug-response characterization of patient-derived prostate cancer primary cells
文献类型：期刊论文
| 作者 | Wang, Ziruoyu8; Li, Yanan7; Zhao, Wensi5,6; Jiang, Shuai3,4; Huang, Yuqi5,6; Hou, Jun4; Zhang, Xuelu2; Zhai, Zhaoyu2; Yang, Chen1; Wang, Jiaqi8 |
| 刊名 | Signal Transduction and Targeted Therapy
 |
| 出版日期 | 2023-05-01 |
| 卷号 | 8期号:6页码:3013-3028 |
| ISSN号 | 2095-9907 |
| DOI | 10.1038/s41392-023-01393-9 |
| 文献子类 | Article |
| 英文摘要 | Prostate cancer (PCa) is the second most prevalent malignancy in males across the world. A greater knowledge of the relationship between protein abundance and drug responses would benefit precision treatment for PCa. Herein, we establish 35 Chinese PCa primary cell models to capture specific characteristics among PCa patients, including gene mutations, mRNA/protein/surface protein distributions, and pharmaceutical responses. The multi-omics analyses identify Anterior Gradient 2 (AGR2) as a pre-operative prognostic biomarker in PCa. Through the drug library screening, we describe crizotinib as a selective compound for malignant PCa primary cells. We further perform the pharmacoproteome analysis and identify 14,372 significant protein-drug correlations. Surprisingly, the diminished AGR2 enhances the inhibition activity of crizotinib via ALK/c-MET-AKT axis activation which is validated by PC3 and xenograft model. Our integrated multi-omics approach yields a comprehensive understanding of PCa biomarkers and pharmacological responses, allowing for more precise diagnosis and therapies. |
| 语种 | 英语 |
| CSCD记录号 | CSCD:7504101 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/309633]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Ye, Mingliang; Tan, Minjia; Jiang, Haowen; Dang, Yongjun |
| 作者单位 | 1.Department of Urology, Huashan Hospital, Fudan University, 200040 Shanghai, China 2.Center for Novel Target and Therapeutic Intervention, Chongqing Medical University, 400016 Chongqing, China; 3.Department of Urology, Zhongshan Hospital Wusong Branch, Fudan University, 200032 Shanghai, China; 4.Department of Urology, Zhongshan Hospital, Fudan University, 200032 Shanghai, China; 5.University of Chinese Academy of Sciences, 100049 Beijing, China; 6.The Chemical Proteomics Center and State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203 Shanghai, China; 7.CAS Key Lab of Separation Sciences for Analytical Chemistry, National Chromatographic Research and Analysis Center, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 116023 Dalian, China; 8.Key Laboratory of Metabolism and Molecular Medicine, The Ministry of Education, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, 200032 Shanghai, China; |
| 推荐引用方式 GB/T 7714 | Wang, Ziruoyu,Li, Yanan,Zhao, Wensi,et al. Integrative multi-omics and drug-response characterization of patient-derived prostate cancer primary cells[J]. Signal Transduction and Targeted Therapy,2023,8(6):3013-3028. |
| APA | Wang, Ziruoyu.,Li, Yanan.,Zhao, Wensi.,Jiang, Shuai.,Huang, Yuqi.,...&Dang, Yongjun.(2023).Integrative multi-omics and drug-response characterization of patient-derived prostate cancer primary cells.Signal Transduction and Targeted Therapy,8(6),3013-3028. |
| MLA | Wang, Ziruoyu,et al."Integrative multi-omics and drug-response characterization of patient-derived prostate cancer primary cells".Signal Transduction and Targeted Therapy 8.6(2023):3013-3028. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。